Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04574401 · ClinicalTrials.gov registry record · Phase 1

A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy

A Phase 1 study of Prostate Cancer, sponsored by Intuitive Surgical.

Completed
Registry status
Phase 1
Development phase
24
Enrollment target
1
Study location

NCT04574401: Completed Phase 1 study of Prostate Cancer, sponsored by Intuitive Surgical.

NCT04574401 is a Phase 1 study of Prostate Cancer that has completed, run by Intuitive Surgical. The registered enrollment target is 24 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT04574401, a Phase 1 study of Prostate Cancer, has completed, sponsored by Intuitive Surgical.

COMPLETED
Registry status
Phase 1
Development phase
24 participants
Enrollment target
1
Study location

Study Summary

This is a Phase 1, single-site, interventional clinical trial evaluating the safety and efficacy of IS-002 intravenous (IV) injection for fluorescent identification and delineation of the positive cancer margins and metastatic lymph nodes during prostatectomy surgery using the da Vinci® X/Xi Surgical System with Firefly® Fluorescent Imaging.

Primary Outcome

Number of participants treated with IS-002 with treatment-emergent adverse events as assessed by CTCAE v5.0

Conditions Studied

Interventions

  • DRUG IS-002

Study Locations (1)

California

  • UCSF Medical Center, Mission Bay - San Francisco

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2020-10-10
Est. Completion 2021-09-20
Phase Phase 1
Intuitive Surgical

40 total trials

What the finished NCT04574401 record still lists

NCT04574401 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which IS-002 is the first listed.

NCT04574401 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT04574401 about?

NCT04574401 is a clinical study titled "A Phase 1 Study of IS-002 Injection in Patients Undergoing Robotic Prostatectomy". This is a Phase 1, single-site, interventional clinical trial evaluating the safety and efficacy of IS-002 intravenous (IV) injection for fluorescent identification and delineation of the positive cancer margins and metastatic lymph nodes during prostatectomy surgery using the da Vinci® X/Xi Surgica...

What is the current status of trial NCT04574401?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-10-10. Estimated completion is 2021-09-20.

What conditions does trial NCT04574401 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT04574401?

The interventions under investigation include: IS-002 (DRUG).

Who is sponsoring clinical trial NCT04574401?

This trial is sponsored by Intuitive Surgical, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04574401 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04574401's enrollment target sits among peer trials

24 634th of 735 higher than 97 of 735 other Prostate Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostate Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04574401, the US trial registry maintained by the National Library of Medicine. NCT04574401 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.